Lough, Tony
Luo, Qingyang
Luxmanan, Carthika
Anderson, Alastair
Suttie, Jimmy
O’Sullivan, Paul
Darling, David
Funding for this research was provided by:
Pacific Edge Limited
Article History
Received: 31 July 2017
Accepted: 26 February 2018
First Online: 9 March 2018
Ethics approval and consent to participate
: Patients consented to the anonymous use of their urine sample, and clinical information derived from it, in the course of prospective clinical studies of Cxbladder. Ethics approval has been obtained from Human Research Ethics Committee (HREC) of Melbourne Health issued 27th June 2016 (HREC/14/MH/230) for Royal Melbourne Hospital and Royal Brisbane Women’s Hospital and also approved by Bellberry HREC under application number 2013-12-684 on 23rd April 2014 for Australian Urology Associates. Separately, approval was obtained from Austin Health HREC (HREC/17/Austin/30) in June 2013 for Northern Hospital.
: Not applicable
: All authors are, or were at the time the study was conducted, employees or contractors of Pacific Edge Ltd. Darling, Luxmanan, O’Sullivan and Suttie, also hold shares and/or share options in Pacific Edge Ltd., a public company whose shares trade on the New Zealand Stock Exchange. O’Sullivan and Darling are listed as applicants in a Patent Cooperation Treaty application, and a corresponding US patent application, covering this technology and Suttie has advised on the filing of this application.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.